Establishment, Characterisation and Partial Cytokine Expression Profile of a New Human Osteosarcoma Cell Line (CAL 72)
Overview
Authors
Affiliations
Permanent human osteosarcoma cell lines are important tools for the study of bone cancer. As representative of an osteoblastic phenotype, they partly reflect their normal osteoblastic counterparts and, thus, may represent appropriate models to investigate the mechanisms involved in bone remodelling and in haematopoietic differentiation. In the present work, we describe a new human cell line, CAL 72, obtained from an osteosarcoma of the knee of a 10-year-old boy. These cells grow in continuous culture, and karyotypic analysis has revealed clonal abnormalities in number and structure, especially loss of chromosome Y. These cells exhibit morphological, immuno-histochemical and molecular characteristics of the osteoblastic lineage. Using RT-PCR, we have shown that the CAL 72 cell line expresses high levels of mRNA coding for several cytokines, such as G-CSF, GM-CSF, IL-1beta and IL-6. In view of this expression profile, the CAL 72 phenotype appears to be closer to normal primary osteoblasts than other reported osteosarcomas. Moreover, these cells express mRNA for both HGF and its receptor c-MET, suggesting that this autocrine loop might contribute to the invasiveness of the tumour from which CAL 72 originated.
Chow T, Humble W, Lucarelli E, Onofrillo C, Choong P, Di Bella C iScience. 2024; 27(9):110251.
PMID: 39286504 PMC: 11403063. DOI: 10.1016/j.isci.2024.110251.
Targeting iron metabolism in osteosarcoma.
Ma X, Zhao J, Feng H Discov Oncol. 2023; 14(1):31.
PMID: 36897430 PMC: 10006389. DOI: 10.1007/s12672-023-00637-y.
Origin and Therapies of Osteosarcoma.
Moukengue B, Lallier M, Marchandet L, Baudhuin M, Verrecchia F, Ory B Cancers (Basel). 2022; 14(14).
PMID: 35884563 PMC: 9322921. DOI: 10.3390/cancers14143503.
Mangelinck A, Marques Da Costa M, Stefanovska B, Bawa O, Polrot M, Gaspar N Sci Rep. 2019; 9(1):12301.
PMID: 31444479 PMC: 6707240. DOI: 10.1038/s41598-019-48846-2.
Surface proteomic analysis of osteosarcoma identifies EPHA2 as receptor for targeted drug delivery.
Posthumadeboer J, Piersma S, Pham T, van Egmond P, Knol J, Cleton-Jansen A Br J Cancer. 2013; 109(8):2142-54.
PMID: 24064975 PMC: 3798973. DOI: 10.1038/bjc.2013.578.